2022
Thrombosis questions from the inpatient wards
Goshua G, Bendapudi P, Lee A. Thrombosis questions from the inpatient wards. Hematology 2022, 2022: 481-490. PMID: 36485139, PMCID: PMC9819989, DOI: 10.1182/hematology.2022000384.Peer-Reviewed Original ResearchConceptsCancer-associated thrombosisInpatient wardsPurpura fulminansIntermediate-dose anticoagulationEtiology of thrombocytopeniaMajor clinical trialsCases of thrombosisCoronavirus disease 2019Recent prospective dataCOVID-19Antithrombin replacementAnticoagulation therapyAntiplatelet therapyAntithrombotic therapyAnticoagulation managementMicrovascular thrombosisPlasma transfusionHospitalized patientsAntiplatelet agentsThromboembolic diseasePlatelet countConsensus guidelinesProspective dataClinical trialsDisease 2019
2020
Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
Goshua G, Liu Y, Meizlish M, Fine R, Amin K, Chang E, Liu Y, McManus D, Petrosan A, Chaar C, Chun H, Defilippo N, Neuberg D, Owusu K, Lee A. Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. Blood 2020, 136: 23-24. PMCID: PMC8330288, DOI: 10.1182/blood-2020-143349.Peer-Reviewed Original ResearchIntermediate-dose anticoagulationAnti-platelet therapyAnticoagulation cohortOverall cohortMultivariable regression modelingRothman IndexDose anticoagulationHospital deathD-dimerPropensity scoreHospitalized patientsMechanical ventilationClinical trialsCOVID-19Prophylactic-dose anticoagulationRisk-stratified algorithmUse of aspirinChronic kidney diseasePropensity-Matched AnalysisEfficacy of aspirinSeverity of illnessAnti-platelet agentsMulti-site cohortImpact of aspirinSmall vessel thrombosis